Pilot study comparing recombinant erythropoietin alone with erythropoietin plus recombinant granulocyte-macrophage colony-stimulating factor for treatment of the anemia of prematurity.
Sixteen infants with the anemia of prematurity were randomly assigned to treatment with packed erythrocyte transfusions, recombinant erythropoietin alone, or epo plus recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). During the treatment period, blood reticulocyte concentrations remained unchanged in those randomly assigned to receive transfusions, but increased significantly in those who received erythropoietin, either alone or in combination with GM-CSF. The magnitude of increase in hematocrit was not greater in those who received erythropoietin plus GM-CSF than in those who received erythropoietin alone. Blood neutrophil concentrations fell in all four infants who received erythropoietin alone, but increased in all who received erythropoietin plus GM-CSF.
Clinical Research Center, University of Utah School of Medicine, Salt Lake City 84132.
R D
RD
Christensen
D D
DD
Hunter
R K
RK
Ohls
D000751:Anemia, Neonatal / Q000097:blood / Q000628:therapy*; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006400:Hematocrit; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000097:blood / Q000628:therapy*; D007958:Leukocyte Count; D008297:Male; D009504:Neutrophils; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000627:therapeutic use; D017701:Reticulocyte Count
D011994:Recombinant Proteins; D004921:Erythropoietin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor